Trial-Results center  
Clinical trial results database in cardiology Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

DVT prophylaxis - anticoagulant - orthopedic surgery

DVT prophylaxis - antithrombotics - orthopedic surgery


Related trials

Gardecki, 3000 - Ticlopidine vs placebo

Lyon-II, 3000 - Ticlopidine vs placebo

ADVANCE 2, 2010 - apixaban vs enoxaparin (europe regimen)

ADVANCE 3, 2010 - apixaban vs enoxaparin

RECORD 4, 2009 - rivaroxaban vs enoxaparin (US regimen)

DRIVE, 2008 - SR123781A vs enoxaparin

RECORD 3, 2008 - rivaroxaban vs enoxaparin (europe regimen)

RE-MOBILIZE (150mg), 2008 - dabigatran 150mg vs enoxaparin (US regimen)

RECORD 2, 2008 - rivaroxaban (long duration) vs enoxaparin (short duration)

RE-MOBILIZE (220mg), 2008 - dabigatran 220mg vs enoxaparin (US regimen)

RECORD 1, 2008 - rivaroxaban vs enoxaparin

ADVANCE-1, 2008 - apixaban vs enoxaparin (US regimen)

RE-NOVATE (220mg), 2007 - dabigatran 220mg vs enoxaparin

Cohen (L8405), 2007 - compression stocking group vs control (on top fondaparinux)

RE-MODEL (220mg), 2007 - dabigatran 220mg vs enoxaparin (europe regimen)

RE-NOVATE (150mg), 2007 - dabigatran 150mg vs enoxaparin

APROPOS 2.5mg, 2007 - apixaban vs enoxaparin (US regimen)

RE-MODEL (150mg), 2007 - dabigatran 150mg vs enoxaparin (europe regimen)

ODIXa-HIP 10mg, 2006 - rivaroxaban vs enoxaparin (short duration)

ODIXa-KNEE, 2005 - rivaroxaban vs enoxaparin (US regimen)

EXPRESS, 2003 - ximelagatran vs Enoxaparin

Platinum (Colwell), 2003 - ximelagatran vs Enoxaparin

PENTHIFRA–PLUS (Eriksson), 2003 - extended prophylaxis vs standard prophylaxis

PENTATHLON (Turpie), 2002 - fondaparinux vs enoxaparin

METHRO III, 2002 - ximelagatran vs Enoxaparin



See also:

  • All DVT prophylaxis clinical trials
  • All clinical trials of antithrombotics
  • All clinical trials of Acenocoumarol
  •  

    Hamulyak study, 1994

    download pdf: Acenocoumarol | antithrombotics for DVT prophylaxis

    Treatments

    Studied treatment Acenocoumarol
    Control treatment Nadroparin 60 anti-Xa IU /kg x1

    Patients

    Patients THR or TKR (stratified)

    Method and design

    Randomized effectives 342 / 330 (studied vs. control)
    Blinding single blind
    Follow-up duration Day 10 ± 2


    Results

    Endpoint Studied treat.
    n/N
    Control treat.
    n/N
    Graph RR [95% CI]

    Deep vein thrombosis

    50 / 257
    43 / 260
    1,18 [0,81;1,70]

    Symptomatic pulmonary embolism

    0 / 342
    0 / 330
    classic 0,96 [0,00;246,15]

    proximal DVT

    15 / 257
    17 / 260
    0,89 [0,46;1,75]

    Major bleeding

    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Ref
    Studied treat. Control treat.
    Deep vein thrombosis 50 / 257 (19,5%) 43 / 260 (16,5%) 1,18 [0,81;1,70]
    Symptomatic pulmonary embolism 0 / 342 (0,1%) 0 / 330 (0,2%) 0,96 [0,02;48,49]
    proximal DVT 15 / 257 (5,8%) 17 / 260 (6,5%) 0,89 [0,46;1,75]
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    Deep vein thrombosis 19,46% 16,54% 2,9%
    proximal DVT 5,84% 6,54% -7,0‰

    Meta-analysis of all similar trials:

    anticoagulant in DVT prophylaxis for orthopedic surgery

    antithrombotics in DVT prophylaxis for orthopedic surgery



    Reference(s)

    Trials register # NA
    • Hamulyák K, Lensing AW, van der Meer J, Smid WM, van Ooy A, Hoek JA. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group.. Thromb Haemost 1995;74:1428-31
      Pubmed | Hubmed | Fulltext

    (c) 2004-2011 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend